FDA Accepts New Drug Application for Zanubrutinib Combination for R/R Follicular Lymphoma

Zanubrutinib combined with obinutuzumab was previously granted both Fast Track and Orphan drug designations for patients with relapsed or refractory follicular lymphoma.

Read the full article here

Related Articles